Biotech · Public company · New York, NY, US

Lb Pharmaceuticals Inc

Ticker LBRX · SEC CIK 0001691082

Track this companyFree. Adds Lb Pharmaceuticals Inc to your Dealase workspace and tells you when its record changes.

Clinical trials63 recruiting or active

Pipeline programs4From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline4

52-week Open Label Safety-Tolerability StudyPHASE3 · RECRUITING · started Apr 23, 2026ClinicalTrials.gov NCT07369154 · fetched Nov 12, 2026
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute SchizophreniaPHASE3 · RECRUITING · started Mar 25, 2026ClinicalTrials.gov NCT07363577 · fetched Nov 12, 2026
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.PHASE2 · RECRUITING · started Jan 23, 2026ClinicalTrials.gov NCT07494305 · fetched Nov 12, 2026
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute SchizophreniaPHASE2 · COMPLETED · started Nov 29, 2023ClinicalTrials.gov NCT06179108 · fetched Nov 12, 2026
Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy VolunteersPHASE1 · COMPLETED · started Jan 5, 2021ClinicalTrials.gov NCT04588129 · fetched Nov 12, 2026
Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy AdultsPHASE1 · COMPLETED · started Jan 22, 2020ClinicalTrials.gov NCT04187560 · fetched Nov 12, 2026